Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Stock Information for Revelation Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revelation Biosciences Inc.

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.